Several Manufacturers and/or Distributors of Popular Heartburn Medication Issue Ranitidine Recall Over Possible Cancer Causing Contaminent.
In late 2019 and early 2020, various companies that manufacture and/or distribute the heartburn and antacid drug ranitidine issued recalls of the medication due to possible exposure to N-nitrosodimethylamine (NDMA), a susbtance that potentially could cause cancer. Ranitidine is the generic version of Zantac.
On February 27, 2020, American Health Packaging voluntarily recalled certain lots of Ranitidine Tablets, USP 150 mg, 100 count Unit Dose Blisters due to the potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. AHP had also recalled certain Ranitidine lots on November 8, 2019.
On January 7, 2020, Appco Pharma LLC voluntarily recalled all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules (Ranitidine Capsules 300 mg and Ranitidine Capsules 150 mg) because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA, based on FDA-validated tests.
On January 6, 2020, Denton Pharma, Inc. dba Northwind Pharmaceuticals, an affiliate of Northwind Pharmaceuticals, LLC (“Northwind”) announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300mg, according the FDA.
On December 17, 2019 Glenmark Pharmaceutical Inc., USA announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300 mg.
On November 8, 2019 Amneal Pharmaceuticals, LLC announced that it was voluntarily recalling Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL.
On November 19, 2019 Precision Dose Inc. announced that it was voluntarily recalling certain lots of Ranitidine Oral Solution, USP 150 mg/10 mL.
On November 15, 2019 Golden State Medical Supply, Incorporated voluntarily instituted a recall of all quantities and lots, within expiry, of Ranitidine HCl 150mg and 300mg Capsules.
On November 6, 2019 Aurobindo Pharma USA, Inc. announced a voluntary recall of certain lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and/or Ranitidine Syrup 15mg/mL.
On October 25, 2019, Novitium Pharma LLC announced that it was voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules in the US (Ranitidine Capsules 150mg and Ranitidine Capsules 300mg).
On October 25, 2019 Lannett Company, Inc. announced that it was voluntarily recalling all lots within expiry of Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL.
On October 23, 2019, Perrigo Company plc announced that it initiated a voluntary, worldwide product recall of ranitidine (all pack sizes) due to possible presence of a nitrosamine impurity called N-nitrosodimethylamine (NDMA).
On September 25, 2019 Apotex Corp. announced that it was voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats, including Walgreens Wal-Zan and Rite Aid Ranitidine tablets, among others).
On September 23, 2019 Sandoz Inc. announced that it was voluntarily recalling all quantities and lots within expiryof Ranitidine Hydrochloride Capsules in the US (Ranitidine 150mg Capsules and Ranitidine 300mg Capsules).
On October 23, 2019, Dr. Reddy’s Laboratories Ltd. confirmed it had intiatiated a voluntary nationwide recall of all of its ranitidine medications sold in the US, including ranitidine sold at or under the following brands: Sam’s Club, Walgreens, Walmart, Kroger, CVS, CDMA, Dr. Reddy, GeriCare, Thirty Madison, and Target.
If you took recalled ranitidine and were diagnosed with cancer, you may be able to seek compensation from a Ranitidine recall lawsuit.
If You Have Thoughts On The Ranitidine Recall, Share Your Comments Below.